Article
Medicine, General & Internal
Cristina Lopez, Birgit Burkhardt, John K. C. Chan, Lorenzo Leoncini, Sam M. Mbulaiteye, Martin D. Ogwang, Jackson Orem, Rosemary Rochford, Mark Roschewski, Reiner Siebert
Summary: Burkitt lymphoma (BL) is an aggressive B cell lymphoma affecting both children and adults. Research has identified key chromosomal aberrations, the role of MYC and Epstein-Barr virus in tumorigenesis. Differentiating between epidemiological variants of BL based on EBV status may better describe the biological heterogeneity of the disease. Diagnosis and treatment of BL vary between children and adults, with generally good outcomes observed in high-income countries.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Biochemistry & Molecular Biology
Rong Shen, Di Fu, Lei Dong, Mu-Chen Zhang, Qing Shi, Zi-Yang Shi, Shu Cheng, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Summary: Genetic classification is essential for identifying genetic subtypes of DLBCL and guiding targeted therapy. The LymphPlex algorithm, based on mutations and rearrangements of specific genes, successfully identified seven distinct subtypes. The genetic subtypes showed different clinical outcomes and biological characteristics, providing potential targets for personalized treatment approaches.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Emilio Bellitti, Pierluigi Masciopinto, Pellegrino Musto, Elena Arcuti, Luca Mastracci, Giuseppina Opinto, Sabino Ciavarella, Attilio Guarini, Gerardo Cazzato, Giorgina Specchia, Eugenio Maiorano, Francesco Gaudio, Giuseppe Ingravallo
Summary: The metachronic onset of diffuse large B-cell lymphoma (DLBCL) after classic Hodgkin lymphoma (cHL) is a rare event affecting patients' outcomes. However, little is known about a hypothetical common origin of the two different neoplastic cells. In this retrospective study, gene expression profile analysis and NanoString Lymphoma Subtype Assay were used to investigate the relationship between DLBCL and cHL. The results showed different immunophenotypic characteristics between the two diseases, but the origin of the second neoplastic cell remains controversial.
Article
Hematology
Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio
Summary: The study found that patients with Burkitt lymphoma who received rituximab treatment had higher survival rates, while factors such as age, ECOG performance status, lactate dehydrogenase levels, and central nervous system involvement could affect patient survival.
Article
Hematology
Kenneth J. C. Lim, Pietro Di Ciaccio, Mark N. N. Polizzotto, Sam Milliken, Tara Cochrane, Zhong Goh, Briony Shaw, Evelyn Perry, Michael Gilbertson, William Kermode, Chan Y. Y. Cheah, Maya Latimer, Nada Hamad, Matthew Ku
Summary: This is a study analysis of patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated in Australia over a 10-year period. The results showed that 80% of patients received chemotherapy with curative intent, rituximab, and concurrent ART with chemotherapy, and the treatment related mortality was 5%. After the end of treatment, 83% of patients achieved a CD4 count of >0.2 x10(9)/L.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Genetics & Heredity
Lotteke J. Y. M. Ziel-Swier, Yichen Liu, Annika Seitz, Debora de Jong, Jasper Koerts, Bea Rutgers, Rianne Veenstra, Fazlyn R. Abdul Razak, Agnieszka Dzikiewicz-Krawczyk, Anke van den Berg, Joost Kluiver
Summary: The MYC/miR-150/MYB/ZDHHC11 network plays a critical role in the growth of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) cells, similar to its role in Burkitt lymphoma (BL) cells. However, the levels of miR-150 appear to have less impact on the growth of HL and DLBCL cells despite effective targeting of ZDHHC11 and MYB.
Review
Oncology
Alexey Danilov, Massimo Magagnoli, Matthew J. Matasar
Summary: DLBCL is a disease characterized by clinical and molecular heterogeneity, which is often overlooked in standard-of-care treatment. Recent classification systems have provided a better understanding of the subtypes and enabled targeted therapies. Molecular subtyping at diagnosis can lead to personalized treatment and advance the use of precision medicine in lymphoma.
Article
Cell Biology
Wei Wang, Shi-wen Xu, Ya Teng, Min Zhu, Qun-yi Guo, Yuan-wen Wang, Xin-Li Mao, Shao-wei Li, Wen-da Luo
Summary: The study showed that a significant portion of pyroptosis-related genes are dysregulated in DLBCL and are associated with prognosis. Three distinct pyroptosis-related clusters were identified in DLBCL patients, showing significant differences in prognosis, biological processes, clinical characteristics, chemotherapeutic drug sensitivity, and tumor immune microenvironment. A risk score signature was developed to effectively differentiate high-risk and low-risk patients, and a nomogram incorporating this signature with clinical indicators demonstrated excellent predictive ability for DLBCL patient prognosis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Hematology
Waleed Alduaij, Brett Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K. Hilton, Merrill Boyle, Barbara Meissner, Lauren Chong, Tomoko Miyata-Takata, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Andrew Lytle, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Randy D. Gascoyne, Joseph M. Connors, Ryan D. Morin, Laurie H. Sehn, Andrew J. Mungall, Christian Steidl, David W. Scott
Summary: This study found that the molecular heterogeneity of DLBCL leads to variable outcomes with immunochemotherapy. DZsig expression extends beyond HGBCL-DH-BCL2 and captures a poor-prognosis DLBCL subgroup with short DTI, including patients unidentifiable by routine FISH testing, that should be considered for treatment intensification or novel therapies in prospective trials.
Article
Hematology
Nicole Thomas, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton, Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, Nancy L. Bartlett, Jeffrey Bethony, Kishor Bhatia, Jay Bowen, Anthony C. Bryan, Ethel Cesarman, Corey Casper, Amy Chadburn, Manuela Cruz, Dirk P. Dittmer, Maureen A. Dyer, Pedro Farinha, Julie M. Gastier-Foster, Alina S. Gerrie, Bruno M. Grande, Timothy Greiner, Nicholas B. Griner, Thomas G. Gross, Nancy L. Harris, John D. Irvin, Elaine S. Jaffe, David Henry, Rebecca Huppi, Fabio E. Leal, Michael S. Lee, Jean Paul Martin, Marie-Reine Martin, Sam M. Mbulaiteye, Ronald Mitsuyasu, Vivian Morris, Charles G. Mullighan, Andrew J. Mungall, Karen Mungall, Innocent Mutyaba, Mostafa Nokta, Constance Namirembe, Ariela Noy, Martin D. Ogwang, Abraham Omoding, Jackson Orem, German Ott, Hilary Petrello, Stefania Pittaluga, James D. Phelan, Juan Carlos Ramos, Lee Ratner, Steven J. Reynolds, Paul G. Rubinstein, Gerhard Sissolak, Graham Slack, Shaghayegh Soudi, Steven H. Swerdlow, Alexandra Traverse-Glehen, Wyndham H. Wilson, Jasper Wong, Robert Yarchoan, Jean C. ZenKlusen, Marco A. Marra, Louis M. Staudt, David W. Scott, Ryan D. Merin
Summary: By sequencing the whole genome of 230 Burkitt lymphoma (BL) and 295 diffuse large B-cell lymphoma (DLBCL) tumors, additional significantly mutated genes were identified, new subtypes of BL and DLBCL were discovered, and genetic features associated with patient outcomes were determined. These findings highlight the shared pathogenesis between adult BL and pediatric BL, and provide a new framework for epidemiology, diagnosis, and therapeutic strategies.
Review
Oncology
Luca Nassi, Vitaliana De Sanctis, Giacomo Loseto, Chiara Gerardi, Eleonora Allocati, Sabino Ciavarella, Carla Minoia, Attilio Guarini, Alessia Bari
Summary: The study aims to bridge the gap in literature regarding long-term lymphoma survivors by examining the incidence of second malignancies and proposing personalized risk prevention strategies. The findings highlight the importance of tailored screening programs for early detection of secondary cancers.
Article
Pathology
Adam S. Bronson, Cullen M. Lilley, Mathew Zleczewski, Kamran M. Mirza
Summary: Polyamines are essential cationic molecules for cell survival and growth, regulated by two enzymes, SAT1 and ODC1. SAT1 degrades polyamines through acetylation, while ODC1 converts polyamine precursors to more complex forms. While polyamines and their regulatory enzymes are known to be involved in various cancers, their role in B-cell malignancies has not been evaluated. Our study found SAT1 expression in all examined cases of DLBCL and HL, with varying levels, primarily in tumor-associated histiocytes rather than tumor cells. These findings suggest an unappreciated role of SAT1 in the pathogenesis of B-cell neoplasms.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Oncology
Xiaoyan Wang, Lu Yu, Xinlu Jiang, Kaiyang Ding
Summary: This study evaluated the clinical effect of lenalidomide maintenance therapy in DLBCL patients who responded to first-line R-CHOP treatment. The results showed that lenalidomide maintenance therapy significantly prolonged the progression-free survival of DLBCL patients, but had no significant impact on overall survival.
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)